
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences is poised for significant advancements in its product pipeline, particularly with the potential of TYRA-300 to improve clinical outcomes such as annual height velocity and associated clinical sequelae. The company's strategic emphasis on multiple indications for TYRA-300, along with the initiation of trials for lower doses across varied patient cohorts, underscores a proactive development approach as it anticipates a busy 2025. Furthermore, Tyra's innovative SNAP platform enhances its drug design capabilities, positioning the company to effectively target large opportunities in FGFR biology and strengthen its competitive standing in the biotechnology sector.
Bears say
Tyra Biosciences reported a substantial net loss of $25.6 million, translating to a loss of $0.43 per share, which aligns closely with existing estimates. The company faces significant challenges in its product development pipeline, particularly concerning the safety profiles of its drug candidates compared to existing FGFR inhibitors, which exhibit high toxicity rates and adverse effects. Additionally, there are critical risks associated with clinical or regulatory setbacks for TYRA-300 that could hinder its ability to meet revenue expectations if approved, further contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares